Deletion of the Ig kappa light chain intronic enhancer/matrix attachment region impairs but does not abolish V kappa J kappa rearrangement

Immunity
Y XuD Baltimore

Abstract

Roles of the kappa intronic enhancer (iE kappa) and its associated matrix attachment region (MAR) during B cell development were examined using mutant embryonic stem (ES) cell lines in which the entire region on both chromosomes was replaced with either a recombined LoxP site (E kappa ND) or the PGK-neomycin resistance (PGK-neo(r)) gene (E kappa NI). B cells derived from E kappa ND ES cells had greatly impaired V kappa J kappa rearrangement, normal levels of kappa expression, and kappa:lambda ratios of 1:1 instead of the usual 10:1. Furthermore, lambda-producing hybridomas derived from E kappa ND cells displayed little kappa rearrangement. Thus, the MAR and iE kappa are quantitatively significant for kappa rearrangement but not necessary. In addition, little V kappa J kappa rearrangement could be detected in B cells derived from E kappa NI ES cells, demonstrating that an inserted PGK-neo(r) gene dominantly suppresses V kappa J kappa rearrangement.

References

May 1, 1992·Molecular and Cellular Biology·R M MortensenJ G Seidman
Jul 25, 1992·Proceedings of the National Academy of Sciences of the United States of America·M LaksoH Westphal
Dec 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·D A Ramsden, G E Wu
Dec 1, 1988·The Journal of Experimental Medicine·B Müller, M Reth
Mar 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·D Weaver, D Baltimore
Mar 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·E SidenD Baltimore
Nov 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·S J KorsmeyerP Leder
Apr 14, 1983·Nature·S Tonegawa
Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·Y BergmanD Baltimore
Jan 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·R P PerryJ F Kearney
Sep 8, 1995·Science·R KühnK Rajewsky
May 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·J ChenF W Alt
Mar 5, 1996·Proceedings of the National Academy of Sciences of the United States of America·Y XuD Baltimore

❮ Previous
Next ❯

Citations

Mar 21, 2000·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·S FieringD I Martin
Oct 5, 2010·Archivum Immunologiae Et Therapiae Experimentalis·Michael L SikesJustin M Bradshaw
Apr 1, 1997·Current Opinion in Immunology·R Kühn, F Schwenk
Feb 27, 1999·Current Opinion in Immunology·H Cedar, Y Bergman
May 21, 2005·Nature Reviews. Immunology·Ulrich SiebenlistEstefania Claudio
Oct 9, 1998·The Journal of Experimental Medicine·M W Retter, D Nemazee
Oct 23, 1998·The Journal of Experimental Medicine·J P ManisF W Alt
Apr 14, 2004·The Journal of Experimental Medicine·Melanie W QuongCornelis Murre
Nov 3, 2004·The Journal of Experimental Medicine·Ranjan Sen
Jan 13, 2010·Cold Spring Harbor Perspectives in Biology·David Baltimore
Jul 2, 2003·Genes & Development·Runqing LuHarinder Singh
Jun 24, 1998·Genes & Development·R MostoslavskyY Bergman
Dec 16, 1998·Immunological Reviews·B P SleckmanF W Alt
Dec 16, 1998·Immunological Reviews·M S KrangelX P Zhong
May 23, 1998·Annual Review of Immunology·A Henderson, K Calame
Mar 23, 2004·Annual Review of Immunology·Mila JankovicMichel C Nussenzweig
Mar 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·K J SeidlF W Alt
Oct 27, 1999·Proceedings of the National Academy of Sciences of the United States of America·R J MonroeF W Alt
Sep 28, 2005·Proceedings of the National Academy of Sciences of the United States of America·Thomas PerlotEric Pinaud
Oct 18, 2000·Proceedings of the National Academy of Sciences of the United States of America·C ChaoY Xu
Aug 19, 1997·Proceedings of the National Academy of Sciences of the United States of America·M B AlimzhanovK Pfeffer
Nov 12, 1996·Proceedings of the National Academy of Sciences of the United States of America·C T PhamT J Ley
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·D SchübelerM A Bender
Oct 1, 1996·Current Opinion in Genetics & Development·D M WillerfordF W Alt
Sep 25, 2010·Seminars in Immunology·Ramesh Subrahmanyam, Ranjan Sen
Mar 23, 2012·Immunological Reviews·Mary Kaileh, Ranjan Sen
Jul 10, 2004·Immunological Reviews·Mark S Schlissel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.